Inozyme Pharma, Inc.

NASDAQ:INZY

5.15 (USD) • At close October 17, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2023202220212020201920182001
Operating Activities:
Net Income -71.169-67.061-56.624-56.424-19.724-6.9640
Depreciation & Amortization 1.2940.7440.6740.2170.0830.0260
Deferred Income Tax 1.37800.170000
Stock Based Compensation 7.0377.6727.1642.3080.3010.4440
Change In Working Capital -3.0822.0120.085-0.1110.6011.4310
Accounts Receivables 0000000
Inventory 0000000
Accounts Payables -1.3780.15-0.6752.098-0.0830.8020
Other Working Capital -1.7041.8620.76-2.2090.6840.6290
Other Non Cash Items -6.133-1.1280.37818.036-0.071-4.3740
Operating Cash Flow -70.675-57.761-48.153-35.974-18.81-9.4370
Investing Activities:
Investments In Property Plant And Equipment -0.298-0.41-0.397-0.568-0.139-0.2590
Acquisitions Net 0.0530.005-0.0430.1170.00800
Purchases Of Investments -269.33-151.993-121.967-177.922-24.662-13.5680
Sales Maturities Of Investments 215.982147165.1661.31116.4122.8330
Other Investing Activites -0.053-0.0050.043-0.117-0.0089.2650
Investing Cash Flow -53.646-5.40342.796-117.179-8.3919.0060
Financing Activities:
Debt Repayment -40-4.0500000
Common Stock Issued 85.96968.7380.609115.97222.9731.9450
Common Stock Repurchased 0.2060.09200000
Dividends Paid 0000000
Other Financing Activities 85.96968.7380.00133.840.02331.9450
Financing Cash Flow 125.96972.7880.609149.81222.9731.9450
Other Information:
Effect Of Forex Changes On Cash -0.018-0.0250.0240000
Net Change In Cash 1.6739.599-4.724-3.341-4.23131.5140
Cash At End Of Period 34.58833.26923.6728.39431.73535.9660